The global diabetic ketoacidosis treatment market size was estimated at USD 874.51 million in 2024 and is projected to reach USD 1,272.36 million by 2033, growing at a CAGR of 4.26% from 2025 to 2033. This strong growth trajectory is propelled by the escalating global prevalence of diabetes, particularly type 1 diabetes, which significantly increases the incidence of DKA, a life-threatening complication requiring immediate medical intervention.